PubMed Health⌕ Search

Biomedical subjects

E Seeman

Publications and source records attributed to E Seeman.

At least 109 records · Page 6Linked to original sources

Reduced femoral neck bone density in the daughters of women with hip fractures: the role of low peak bone density in the pathogenesis of osteoporosis.

Low bone density in women with hip fractures ("senile" osteoporosis) may be due to excessive bone loss or low peak bone density. If excessive bone loss is responsible, then no reduction in bone density is expected in their daughters. If low peak bone density is responsible, then bone density should also be reduced in their daughters because genetic and family environmental factors influence the variability in bone density. Bone density was measured using dual-photon absorptiometry and expressed as a standardized deviation or Z score relative to 697 controls, adjusting for age, height, weight, and menopausal status. In 74 women with hip fractures, the Z score (mean +/- SEM) was -0.52 +/- 0.14 (P < 0.001) at the femoral neck, -1.04 +/- 0.17 (P < 0.001) at the femoral shaft, and -0.43 +/- 0.10 (P < 0.001) at the lumbar spine. In their 41 daughters, the Z score was -0.40 +/- 0.17 (P < 0.05) at the femoral neck, -0.41 +/- 0.19 (P < 0.001) at the femoral shaft, and 0.23 +/- 0.13 (NS) at the lumbar spine. We conclude that daughters of women with hip fractures are likely to be at increased risk for hip fractures themselves because they have reduced femoral neck bone density. Femoral neck fractures may not be entirely attributable to trauma; reduced bone density is likely to contribute and may be caused by the attainment of a lower peak femoral neck bone density.

Absorptiometry, Photon↗

Reduced bone density in women with fractures: contribution of low peak bone density and rapid bone loss.

Osteoporosis is regarded as a disease of the elderly because fractures occur late in life. Although excessive bone loss during aging is likely to contribute to the deficit in bone density, patients with fractures do not consistently have more rapid bone loss, greater bone resorption or lower bone formation (measured using biochemical or histomorphometric markers of bone turnover). The pathogenesis of the low bone density and bone fragility that characterize osteoporosis may begin during the first two decades of life. There are differences in the hormonal regulation of regional growth and mineral accrual, differences in the age of onset, rate and duration of linear growth and mineral accrual of the axial and appendicular skeleton, of cortical and trabecular bone, and of proximal and distal limb segments. Illnesses, risk or protective factors, and disorders of hormonal deficiency or excess may affect longitudinal growth, mineral accrual, or both, depending on the timing of exposure. Quantitatively larger and qualitatively different effects on bone density may result when exposure occurs during growth rather than during adulthood. The magnitude of these deficits and their location are likely to establish the relevance of regional age-related and sex hormone dependent bone loss. Thus, any unifying hypothesis concerning the epidemiology and pathogenesis of osteoporosis must consider the relative contributions of low peak bone density and bone loss to the deficit in bone density in adulthood. A great deal of research is needed to examine the physiology of longitudinal growth and mineral accrual as the pathogenesis of osteoporosis is at least partly explained by events occurring during the first 20 years of life.

Age Factors↗

Lean body mass, body surface area and epirubicin kinetics.

For a number of cytotoxics, a relationship between efficacy and plasma concentrations has recently been demonstrated. Lean body mass has been demonstrated to be a useful parameter for predicting drug clearance for a number of non-cytotoxic drugs. However, the role of lean body mass in predicting drug clearance for any cytotoxic drug has not been previously reported. Our purpose was to investigate lean body mass as a predictor of epirubicin clearance. Pharmacokinetic studies were performed in 10 patients receiving single agent epirubicin. Although preliminary, this study suggests that lean body should be further evaluated and tested in dose optimization studies.

Body Mass Index↗

Bone density at weight-bearing and nonweight-bearing sites in ballet dancers: the effects of exercise, hypogonadism, and body weight.

Exercise is recommended as a means of preventing osteoporosis. When intensive, weight-bearing exercise is often associated with hypogonadism. As weight-bearing exercise is likely to be more beneficial at weight-bearing than nonweight-bearing sites, and hypogonadism is likely to be more detrimental to trabecular than cortical bone, we tested the hypothesis that exercise and hypogonadism result in differing regional effects: net benefits at weight-bearing, predominantly cortical sites, and net deficits at nonweight-bearing trabecular-rich sites. Bone density (grams per cm2), body fat, and fat-free mass (kilograms) were measured using dual x-ray absorptiometry in 44 ballet dancers, aged 17.0 +/- 0.2 yr (mean +/- SEM), 18 sedentary amenorrheic girls with anorexia nervosa, and 23 girls of comparable age with regular menstrual cycles. Bone density, expressed as a percentage above or below the mean in the girls with regular menstrual cycles, was normal or elevated at weight-bearing sites in dancers [femoral neck, 3.1 +/- 1.7% (P = NS); Wards triangle, 4.1 +/- 2.3% (P = NS); trochanter, 5.9 +/- 1.9% (P < 0.05)] and normal or reduced at these sites in girls with anorexia nervosa [-10.5 +/- 3.8% (P < 0.05), -7.8 +/- 4.3% (P = NS), and -8.7 +/- 4.0% (P < 0.05), respectively]. By contrast, deficits similar to those in girls with anorexia nervosa were found in dancers at nonweight-bearing sites [ribs, -5.7 +/- 0.8% (P < 0.01); arms, -4.6 +/- 1.1% (P < 0.01); skull, -5.9 +/- 1.3% (P < 0.01)] before, but not after, correcting for fat mass. Fat mass was 7.8 +/- 0.4 kg in dancers, similar to that in girls with anorexia nervosa (6.3 +/- 0.7 kg) and lower than that in girls with regular menstrual cycles (16.8 +/- 1.6 kg; P < 0.01). The net result of vigorous exercise, hypogonadism, and leanness in athletic amenorrhea may not be generalized osteoporosis. Weight-bearing exercise may offset the effects of hypogonadism at predominantly cortical weight-bearing sites, such as the proximal femur. Non-weight-bearing sites and weight-bearing sites containing substantial amounts of trabecular bone, such as the lumbar spine, may be adversely affected by hypogonadism while benefiting little from weight-bearing exercise. Deficits at nonweight-bearing sites may be attenuated by maintenance of body weight.

Absorptiometry, Photon↗

Bone mass during growth: the effects of exercise. Exercise and mineral accrual.

Intense exercise during childhood and adolescence may result in primary amenorrhea and low peak bone mineral density (BMD). After puberty, exercise may result in secondary amenorrhea and bone loss. Higher BMD in amenorrheic athletes than amenorrheic sedentary persons suggests that exercise may partly offsets the effects of amenorrhea. To examine this possibility, we measured BMD (g/cm2) by dual x-ray absorptiometry in 32 ballet dancer and 23 healthy controls of comparable age with regular menstrual cycles, 34 pre-pubertal female gymnasts bone age 8.9 +/- 0.2 years and 37 girls matched by bone age. Dancers had normal BMD at the weight bearing sites, not low, despite having oligomenorrhea, not high despite 32 hours of week dancing. BMD was lower by 4-6 percent at the non-weight bearing sites. BMD diminished in the dancers at the weight bearing femoral neck (r = -0.29, P = 0.1) and trochanter (r = -0.31, P = 0.09), and at the non-weight bearing arms (r = -0.29, P = 0.09) with increasing duration of amenorrhea. Dancers with less than 40 months amenorrhea had 5 to 7% higher BMD at the weight bearing, but not non-weight bearing sites. Dancers with more than 40 months amenorrhea had normal, not higher BMD at weight bearing sites and deficits of about 5 percent at non-weight bearing sites. In gymnasts, BMD was 10-15 percent (or 1 SD) higher than the bone age-predicted mean. Exercise may not offset the effects of amenorrhea. Bone loss may continue but from a higher level, perhaps attained prior puberty.

Adolescent↗

Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities.

The neglect of the problem of fractures in men may be the result of the focus on the enormity of the problem in women, attention to vertebral fractures and the role of menopause in the pathogenesis of fractures and cardiovascular disease, and the role of hormone replacement therapy in the prevention of fractures and cardiovascular disease. The use of epidemiology as a means of understanding the disease in individuals has confirmed that fractures are a common and serious consequence of osteoporosis in women--and in men.

Accidental Falls↗

Body composition following hemodialysis: studies using dual-energy X-ray absorptiometry and bioelectrical impedance analysis.

The detection, prevention and treatment of disease is greatly facilitated by the availability of accurate and non-invasive techniques for measuring the amount and regional distribution of fat mass and fat-free mass. As differing degrees of hydration may influence these measurements, we used dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA) to detect changes in hydration following hemodialysis, and to determine whether fat mass, fat-free mass and bone density measurements were affected by these fluid changes. Ten subjects (7 men, 3 women) mean age 46.2 years (range 25-68 years), with renal failure had bone density, fat-free mass and fat mass measured by DXA, and total body water and fat-free mass measured by BIA, before and after hemodialysis. Thirty-two subjects had fat-free mass measured by DXA and BIA in an attempt to derive new equations (using fat-free mass measured by DXA as the reference standard) to improve the predictive value of BIA. The new equations were then used to derive the changes in fat-free mass following hemodialysis measured using BIA. In absolute terms, total tissue measured by DXA (r = 0.99, p = 0.01) and total body water measured by BIA (r = 0.91, p = 0.01) correlated with gravimetric weight. Following hemodialysis, fat mass and bone density measured by DXA were unaffected by the fluid changes. The change in gravimetric weight was 1.8 +/- 0.3 kg, p = 0.01 (mean +/- SEM). This change was measured as 1.9 +/- 0.3 kg by DXA, -0.9 +/- 1.0 kg by BIA using the published equation for fat-free mass, and 3.2 +/- 0.4 kg using the new equation for fat-free mass.(ABSTRACT TRUNCATED AT 250 WORDS)

Absorptiometry, Photon↗

Long-term glycemic control and the rate of progression of early diabetic kidney disease.

In this prospective study of 11.9 years duration (range 9 to 14), we examined the progression of albuminuria prior to and after the onset of microalbuminuria [albumin excretion rate (AER): 20 to 200 micrograms/minute]. Glycated hemoglobin (HbA1), AER and blood pressure were measured every six months. Twenty-two (13 type I, 9 type II) patients were identified in whom AER increased progressively (progressors). These patients were compared with 22 others matched for age, duration and type of diabetes in whom AER did not change significantly during the study period (non-progressors). In the progressors, the rate of increase in AER correlated with mean HbA1 for the study period in patients with type I (r = 0.68, P < 0.01) and type II diabetes (r = 0.71, P < 0.05). Furthermore, AER began increasing well before the conventional 20 micrograms/minute threshold of microalbuminuria had been reached and within the first five years of diagnosis of type I diabetes. We conclude that in predisposed diabetic patients, long-term glycemic control is correlated with the rate of development of early renal abnormalities. Repeated measurements of AER from the time of diagnosis may be useful in the early detection of patients who will develop microalbuminuria and ultimately overt diabetic nephropathy.

Adolescent↗

Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception.

To determine the effect of androgens on body composition and muscle strength, we measured fat-free mass (kg), fat mass (kg), and bone density (g/cm2) by dual x-ray absorptiometry, and muscle strength (Newton meters) by dynamometry in a controlled, prospective study involving 13 nonathletic men receiving testosterone enanthate 200 mg/week in for 6 months and 8 healthy controls. Biochemical markers of bone turnover were measured in the treated subjects at baseline and 6 months. In the treated subjects at 6 months, fat-free mass (mean +/- SEM) increased by 9.6 +/- 1.0% (P < or = 0.01) whereas fat mass decreased by 16.2 +/- 6.7% (P < or = 0.05). Changes in muscle strength ranged from -1.6-19.2%. Only hip adduction increased 19.2 +/- 9.5% (P < 0.05). Changes in bone density ranged from -1.3-5.2%, decreasing significantly at one site and increasing significantly at four of the nine sites measured (P < 0.05). Serum testosterone increased by 91.1 +/- 7.5% (P < 0.01), and testicular volume decreased by 24.0 +/- 3.2% (P < 0.01). Serum osteocalcin increased by 35.7 +/- 17.3% (P < 0.05), serum immunoreactive PTH (iPTH) increased by 41.4 +/- 15.1% (P < 0.05), serum calcium decreased by 2.3 +/- 1.0% (P < 0.05), and serum albumin decreased by 4.5 +/- 1.7% (P < 0.05). There were no detectable changes in fat-free mass, fat mass, muscle strength, or bone density in controls. The administration of testosterone enanthate in pharmacological doses for 6 months resulted in a modest reduction in fat mass and small increases in fat-free mass, muscle strength, and bone density. These changes do not support the use of androgens for enhancing athletic performance.

Absorptiometry, Photon↗

Peak bone mass, a growing problem?

The focus of attention in osteoporosis research has been on factors influencing bone fragility and the propensity for trauma (falls) during adulthood and old age. The purpose of this review is to change the focus of this attention toward consideration of skeletal growth in the first 20 years of life and to demonstrate the importance of mineral accrual (and the factors influencing this accrual) in determining bone density in adulthood and old age. We suggest that the epidemiology of fractures may be unified by a central role of reduced peak bone density in the pathogenesis of the low bone density found in patients with fractures. The reduced peak bone density establishes the relevance of age-related and sex hormone-dependent bone loss. Risk and protective factors in the first 20 years of life may have quantitatively larger, and qualitatively different effects on the axial and appendicular skeleton than exposure during adulthood. Public health measures focussed on optimising mineral accrual in the first 20 years of life may be more important than health care measures more proximate to the age at which fractures occur.

Adolescent↗

Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise.

Anorexia nervosa occurs early in life and predisposes to osteoporosis. Exercise may be protective. We asked: (1) Does failure to attain peak bone density contribute to the deficit in bone density? (2) Does oral contraceptive use protect against osteoporosis? (3) Is any protective effect of exercise confined to weight-bearing sites? Areal bone density (g/cm2) and body composition were measured by dual x-ray absorptiometry in 65 patients with anorexia nervosa and 52 controls. Comparing the 12 patients with primary amenorrhea and the 37 patients with secondary amenorrhea, bone density (mean +/- SEM) at the lumbar spine was 0.88 +/- 0.04 versus 1.06 +/- 0.03 (P = 0.001), respectively. Bone density at the femoral neck was 0.80 +/- 0.04 versus 0.92 +/- 0.03 (P < 0.05), respectively. These values differed before, but not after, adjusting for the respective duration of illness (73.0 +/- 10.3 versus 34.1 +/- 4.8 months, P < 0.001) and fat-free mass (31.6 +/- 1.3 versus 35.4 +/- 0.5 kg, P < 0.01). Bone density at the lumbar spine in the 16 patients with 31.8 +/- 8.3 months of contraceptive exposure was higher than in the 49 patients with no contraceptive exposure (1.14 +/- 0.05 versus 1.02 +/- 0.02 P < 0.02) but was lower than in controls (1.14 +/- 0.05 versus 1.27 +/- 1.02, P < 0.01). No protective effect of contraceptive exposure was detectable at the femoral neck.(ABSTRACT TRUNCATED AT 250 WORDS)

Absorptiometry, Photon↗

Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.

The effects of the antiandrogen drugs cyproterone acetate (CPA) and spironolactone on hair growth and androgen levels were compared in a randomized study of 48 hirsute women. Twenty six subjects completed 6 months of therapy with 100 mg/day CPA and 19 subjects completed 6 months of 100 mg/day spironolactone. All except 10 subjects received concomitant estrogen therapy. Measured objectively, total hair diameter fell by 17.1% with spironolactone (P less than 0.001), and by 16.8% with CPA (P less than 0.001). The diameter of the hair medulla fell by 17.8% with spironolactone (P less than 0.01), and by 31.7% with CPA (P less than 0.001). There was no difference between the drugs in their effect on hair diameter. Plasma testosterone levels also fell significantly with both drugs. As a subjective assessment of treatment efficacy, the frequency with which subjects performed cosmetic measures was recorded. This fell by 38% with spironolactone and by 44.7% with CPA (P less than 0.001 both drugs), and again there was no difference between the drugs. Side effects caused cessation of treatment in one subject taking CPA and two subjects taking spironolactone, and milder side effects were noted in two further subjects from each treatment group. We conclude that spironolactone and CPA, in the dosages used in this study, are effective and well tolerated agents for the treatment of hirsutism, and that neither drug demonstrates a particular advantage over the other.

Adult↗

Reduced bone mass in daughters of women with osteoporosis.

To determine whether premenopausal daughters of women with postmenopausal osteoporosis have lower bone mass than other women of the same age, we measured the bone mineral content of the lumbar spine and femoral neck and midshaft, using dual-photon absorptiometry, in 25 postmenopausal women with osteoporotic compression fractures and in 32 of their premenopausal daughters; we then compared the results with those in normal controls. As compared with normal postmenopausal women, women with osteoporosis had lower bone mineral content in the lumbar spine, femoral neck, and femoral midshaft by 33, 24, and 15 percent, respectively (P less than 0.001 for each comparison by the one-tailed t-test). As compared with normal premenopausal women, the daughters of women with osteoporosis had lower bone mineral content at these sites by 7, 5, and 3 percent, respectively (P = 0.03, 0.07, and 0.15, respectively, by the one-tailed t-test). In terms of a standardized score, we calculated that the mean (+/- SEM) relative deficits in bone mineral content in the daughters of women with osteoporosis were 58 +/- 18 percent (lumbar spine) and 34 +/- 16 percent (femoral neck) of the relative deficits in their mothers. We conclude that daughters of women with osteoporosis have reduced bone mass in the lumbar spine and perhaps in the femoral neck; this reduction in bone mass may put them at increased risk for fractures. We also conclude that postmenopausal osteoporosis may result partly from a relatively low peak bone mass rather than from excessive loss of bone.

Bone and Bones↗

Non-invasive techniques for the measurement of bone mineral.

Non-invasive, safe and precise techniques for measuring bone mineral density are available and have an important role in the detection, prevention and treatment of bone loss associated with aging, menopause and many illnesses affecting women and men. The three most widely accessible and established techniques for measuring regional bone mineral density are single and dual photon absorptiometry and quantitative computed tomography. A technique of greater accuracy, dual energy X-ray absorptiometry, has only recently become available. These techniques have made it possible to measure the magnitude, time course and regional specificity of the skeleton's response to ageing, menopause and illness. A better understanding of the clinical epidemiology of fractures and the mechanisms responsible for bone loss has been obtained. Practical information has been obtained about the dose, duration and efficacy of oestrogen replacement therapy in preventing perimenopausal bone loss and the benefits and limitations of different forms of exercise on bone mineral density in healthy postmenopausal women. The beneficial effect of dietary calcium on peak bone mineral density and in decreasing bone loss in cortical bone has been documented. Information regarding the prevention and treatment of bone loss in exogenous hypercortisolism and the magnitude and reversibility of bone loss associated with many diseases which affect bone has been obtained. One of the most important clinical applications of these techniques is the assessment of the efficacy of treatment of patients with postmenopausal osteoporosis. As antifracture efficacy is not readily measurable, considerable information is being obtained about many potentially useful forms of therapy that may prevent bone loss and increase bone mineral density. The role of these non-invasive methods in the assessment of fracture risk and the need for oestrogen or other therapy in an individual who has attained a low peak bone mass or has risk factors predisposing to excessive bone loss, differs from broader public health initiatives of population screening. There are concerns regarding the safety, efficacy and limited number of treatment regimens available for persons found by screening to be at risk. The most economic and convenient methods for predicting fracture risk with high sensitivity and specificity are not established. There are uncertainties regarding the relative importance of bone mineral density measured at the time of screening, the amount of bone lost in the subsequent years and risk factors predisposing to falls in the pathogenesis of hip fractures.(ABSTRACT TRUNCATED AT 400 WORDS)

Absorptiometry, Photon↗